SUMMARY To investigate the cause of low serum histidine in rheumatoid arthritis (RA) single oral and intravenous doses of L-histidine were administered to patients with active RA, and to an equal number of age and sex matched control subjects. In the first study 13 patients and their controls received a 100 mg kg-1 dose of L-histidine as an aqueous slurry. Significant differences were seen in body weight, predose baseline serum histidine concentration, Cmax, t,½, and area under curve, AUCOo In a second study six patients and six controls each received a 50 mg kg-1 dose of L-histidine both orally and intravenously on two separate occasions. The patients with RA had a lower baseline serum histidine concentration, a lower volume of distribution, and a shorter plasma half life than the controls, but these differences were not statistically significant. No difference was seen in bioavailability or clearance. Low serum histidine in RA is unlikely to be due to malabsorption from the gut, uptake by abnormal gut flora, or increased metabolism.
The concentration of free serum histidine (i.e., histidine+trace metals-histidine complexes) is significantly decreased in patients with rheumatoid arthritis (RA).1 Gerber has shown that serum histidine levels are related to disease activity in patients with RA.
One possible cause of this hypohistidinaemia is defective absorption from the gut, perhaps due to excessive uptake or metabolism by atypical gut flora. There is some evidence to suggest that patients with chronic polyarthritis have an intestinal flora with the occurrence of atypical strains of Clostridium perfringens type A,2 -for which tryptophan and histidine are essential amino acids. 4 Bergstrom and Havermark showed that the jejunal mucosa of patients with RA had [5] [6] [7] [8] [9] [10] All data sets were fitted to this model and the best values of s0, V, and ke were found together with ka for oral doses. All sets gave an acceptable fit, though s0 differed in some cases from the measured value. Clearance was calculated as kexV (1 h-1).
Basal flux (or turnover) (Fl) was kexVxso (mg h-1) from IV data. Bioavailability (%) was calculated as 1OOxCl (IV)/Cl (oral) and t½h as In 2/ke, where Cl=total body clearance.
Model independent
Computer modelling showed that the data most closely fitted a one compartment model with first order elimination. Maximum serum histidine concentration (Cmax) and time to achieve Cmax (Tmax) were observed directly from the data. (In the case of IV dosing Cmax was the concentration at the completion of the infusion.) The serum histidine half life (t,,½) was obtained by log linear least squares regression analysis of data points following the peak concentration, after subtraction of the baseline histidine concentration from each result.
The area under the serum concentration versus time plot (AUC(>,) was In this study patients were matched to controls not only for age and sex but also for body weight, and hence for dose. Although the absolute results generated by the model dependent (Table 2) and model independent (Table 3) analyses were not identical, the trends in the differences between patients and controls were the same. There were no statistically significant differences between patients and controls for any kinetic parameter, using either the model dependent or model independent results.
The improved matching showed similar AUC0-, results in patients and controls after both oral and IV doses, but the bioavailability was found to be quite variable (52-111%) (Tables 2 and 3 ). The serum t½, was shorter and the Cmax higher in patients than in the controls after oral and IV doses. VD was notably lower in five of the six patients, while Cl showed no difference. There was no significant correlation between dose and any kinetic parameter.
Discussion
Some of the kinetic differences between patients with RA and normal controls observed in the first study may be attributed to the differences in body weight (e.g. AUC0-,). Although the dose was titrated against body weight, this could have confounded the results from this study as the differences might be explained on the basis of the different doses. In the second study the two groups were matched for weight in addition to age and sex, and hence the trends observed in the results might be more reliably attributed to disease. Differences in baseline histidine and t½2 seen in the first study were maintained in the second study, but with the small number of patients in the latter it was not surprising that these failed to achieve statistical significance. There remains the possibility that if a different amino acid was used in a similar loading study that similar results might be obtained in the absence of a difference in baseline levels. Future studies should therefore include a loading study similar to study 2 using an amino acid which shows normal serum levels in RA. To be certain in the selection of the latter, however, the levels of other amino acids in RA require confirmation as previous investigations have only agreed on abnormally low serum histidine. [12] [13] [14] [15] It can be concluded that there is a trend towards a reduction in the distribution volume of a histidine load in patients with RA. This occurs in conjunction with a reduction in serum half life but no change in clearance. There is no evidence for abnormal histidine absorption or increased metabolism in RA, but the precise cause of low serum histidine remains obscure. 
